
Elizabeth A Ashley

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6042221/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, The, 2022, 399, 629-655.	13.7	4,915
2	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
3	Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet, The, 2004, 364, 438-447.	13.7	707
4	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	21.4	515
5	Malaria. Lancet, The, 2018, 391, 1608-1621.	13.7	374
6	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	9.1	363
7	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science, 2015, 347, 431-435.	12.6	362
8	A Major Genome Region Underlying Artemisinin Resistance in Malaria. Science, 2012, 336, 79-82.	12.6	334
9	Antimicrobial resistance in Africa: a systematic review. BMC Infectious Diseases, 2017, 17, 616.	2.9	310
10	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	9.1	252
11	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE, 2009, 4, e4551.	2.5	212
12	Primaquine: the risks and the benefits. Malaria Journal, 2014, 13, 418.	2.3	188
13	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	13.7	182
14	Declining Efficacy of Artemisinin Combination Therapy Against <i>P. Falciparum</i> Malaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors. Clinical Infectious Diseases, 2016, 63, 784-791.	5.8	178
15	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infectious Diseases, The, 2010, 10, 673-681.	9.1	168
16	Drugs in Development for Malaria. Drugs, 2018, 78, 861-879.	10.9	154
17	A current perspective on antimicrobial resistance in Southeast Asia. Journal of Antimicrobial Chemotherapy, 2017, 72, 2963-2972.	3.0	139
18	Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet, The, 2006, 367, 2075-2085.	13.7	133

#	Article	IF	CITATIONS
19	Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics. Clinical Infectious Diseases, 2011, 52, 612-620.	5.8	124
20	Longitudinal genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic architecture of emerging artemisinin resistance. Genome Biology, 2017, 18, 78.	8.8	120
21	Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Neglected Tropical Diseases, 2018, 12, e0006230.	3.0	120
22	How much fat is necessary to optimize lumefantrine oral bioavailability?. Tropical Medicine and International Health, 2007, 12, 195-200.	2.3	118
23	The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. European Journal of Clinical Pharmacology, 2006, 62, 1021-1031.	1.9	112
24	The duration of Plasmodium falciparum infections. Malaria Journal, 2014, 13, 500.	2.3	109
25	A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum Malaria. Clinical Infectious Diseases, 2005, 41, 425-432.	5.8	107
26	Randomized, Controlled Doseâ€Optimization Studies of Dihydroartemisininâ€Piperaquine for the Treatment of Uncomplicated Multidrugâ€Resistant Falciparum Malaria in Thailand. Journal of Infectious Diseases, 2004, 190, 1773-1782.	4.0	104
27	Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia. Malaria Journal, 2017, 16, 195.	2.3	99
28	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
29	Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated <i>Plasmodium falciparum</i> Malaria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3837-3846.	3.2	96
30	Efficacy and safety of artemether–lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infectious Diseases, The, 2010, 10, 762-769.	9.1	96
31	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infectious Diseases, The, 2020, 20, 1470-1480.	9.1	94
32	Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrugâ€resistant falciparum malaria. Tropical Medicine and International Health, 2007, 12, 201-208.	2.3	88
33	Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2017, 34, 131-144.	8.9	87
34	Pharmacokinetic Interactions between Primaquine and Chloroquine. Antimicrobial Agents and Chemotherapy, 2014, 58, 3354-3359.	3.2	78
35	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
36	Antimicrobial susceptibility of bacterial isolates from community acquired infections in Sub‣aharan Africa and Asian low and middle income countries. Tropical Medicine and International Health, 2011, 16, 1167-1179.	2.3	67

#	Article	IF	CITATIONS
37	Arthropod Borne Disease: The Leading Cause of Fever in Pregnancy on the Thai-Burmese Border. PLoS Neglected Tropical Diseases, 2010, 4, e888.	3.0	61
38	Microbiology Investigation Criteria for Reporting Objectively (MICRO): a framework for the reporting and interpretation of clinical microbiology data. BMC Medicine, 2019, 17, 70.	5.5	55
39	Genetic surveillance in the Greater Mekong subregion and South Asia to support malaria control and elimination. ELife, 2021, 10, .	6.0	53
40	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
41	An open label randomized comparison of mefloquine?artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Tropical Medicine and International Health, 2006, 11, 1653-1660.	2.3	50
42	Pregnancy Outcome in Relation to Treatment of Murine Typhus and Scrub Typhus Infection: A Fever Cohort and a Case Series Analysis. PLoS Neglected Tropical Diseases, 2014, 8, e3327.	3.0	50
43	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	8.4	50
44	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
45	An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. Journal of Antimicrobial Chemotherapy, 2018, 73, 1737-1749.	3.0	47
46	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47
47	Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nature Communications, 2019, 10, 2665.	12.8	46
48	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria Journal, 2016, 15, 185.	2.3	43
49	The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malaria Journal, 2008, 7, 149.	2.3	42
50	Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia. Malaria Journal, 2013, 12, 250.	2.3	42
51	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 7340-7346.	3.2	42
52	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 505-513.	3.2	41
53	Electrocardiographic Safety Evaluation of Dihydroartemisinin–Piperaquine in the Treatment of Uncomplicated falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-450.	1.4	41
54	Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. BMC Medicine, 2018, 16, 183.	5.5	40

#	Article	IF	CITATIONS
55	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	5.5	37
56	Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. PLoS Medicine, 2015, 12, e1001823.	8.4	36
57	Treatment and prevention of malaria in children. The Lancet Child and Adolescent Health, 2020, 4, 775-789.	5.6	34
58	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
59	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
60	Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-50.	1.4	32
61	Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Africa, 1980–2015. BMC Medicine, 2020, 18, 279.	5.5	31
62	Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial. Malaria Journal, 2013, 12, 251.	2.3	30
63	Non-malarial febrile illness: a systematic review of published aetiological studies and case reports from Southern Asia and South-eastern Asia, 1980–2015. BMC Medicine, 2020, 18, 299.	5.5	30
64	Defining System Requirements for Simplified Blood Culture to Enable Widespread Use in Resource-Limited Settings. Diagnostics, 2019, 9, 10.	2.6	29
65	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 943-952.	9.1	25
66	Clinical impact of vivax malaria: A collection review. PLoS Medicine, 2022, 19, e1003890.	8.4	25
67	The 20-minute whole blood clotting test (20WBCT) for snakebite coagulopathy—A systematic review and meta-analysis of diagnostic test accuracy. PLoS Neglected Tropical Diseases, 2021, 15, e0009657.	3.0	22
68	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	4.0	21
69	Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. Antimicrobial Agents and Chemotherapy, 2021, 65, e0112121.	3.2	21
70	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLoS Medicine, 2020, 17, e1003040.	8.4	20
71	Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries. Clinical Microbiology and Infection, 2021, 27, 1391-1399.	6.0	20
72	Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity. Journal of Infectious Diseases, 2019, 220, 100-104.	4.0	19

#	Article	IF	CITATIONS
73	Harnessing alternative sources of antimicrobial resistance data to support surveillance in low-resource settings. Journal of Antimicrobial Chemotherapy, 2019, 74, 541-546.	3.0	18
74	ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Research, 2020, 5, 13.	1.8	18
75	Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. BMJ: British Medical Journal, 2015, 350, h602.	2.3	17
76	Poor response to artesunate treatment in two patients with severe malaria on the Thai–Myanmar border. Malaria Journal, 2018, 17, 30.	2.3	16
77	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2020, 18, 138.	5.5	16
78	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16
79	Participants' perceptions and understanding of a malaria clinical trial in Bangladesh. Malaria Journal, 2014, 13, 217.	2.3	14
80	Evaluation of the forum theatre approach for public engagement around antibiotic use in Myanmar. PLoS ONE, 2020, 15, e0235625.	2.5	14
81	Automating the Generation of Antimicrobial Resistance Surveillance Reports: Proof-of-Concept Study Involving Seven Hospitals in Seven Countries. Journal of Medical Internet Research, 2020, 22, e19762.	4.3	14
82	Have we really failed to roll back malaria?. Lancet, The, 2022, 399, 799-800.	13.7	14
83	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
84	Impact of delays to incubation and storage temperature on blood culture results: a multi-centre study. BMC Infectious Diseases, 2021, 21, 173.	2.9	13
85	Laboratory informatics capacity for effective antimicrobial resistance surveillance in resource-limited settings. Lancet Infectious Diseases, The, 2021, 21, e170-e174.	9.1	13
86	ACORN (A Clinically-Oriented Antimicrobial Resistance Surveillance Network): a pilot protocol for case based antimicrobial resistance surveillance. Wellcome Open Research, 2020, 5, 13.	1.8	13
87	Grading antimicrobial susceptibility data quality: room for improvement. Lancet Infectious Diseases, The, 2018, 18, 603-604.	9.1	12
88	Melioidosis in Myanmar. Tropical Medicine and Infectious Disease, 2018, 3, 28.	2.3	12
89	Prediction of disease severity in young children presenting with acute febrile illness in resource-limited settings: a protocol for a prospective observational study. BMJ Open, 2021, 11, e045826.	1.9	12
90	Myanmar Burkholderia pseudomallei strains are genetically diverse and originate from Asia with phylogenetic evidence of reintroductions from neighbouring countries. Scientific Reports, 2020, 10, 16260.	3.3	11

#	Article	IF	CITATIONS
91	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 2021, 6, 64.	1.8	11
92	Antimicrobial use and resistance data in human and animal sectors in the Lao PDR: evidence to inform policy. BMJ Global Health, 2021, 6, e007009.	4.7	11
93	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 0, 6, 64.	1.8	11
94	Measuring Mosquito-borne Viral Suitability in Myanmar and Implications for Local Zika Virus Transmission. PLOS Currents, 2018, 10, .	1.4	10
95	Seasonal malaria chemoprevention: closing the know–do gap. Lancet, The, 2020, 396, 1778-1779.	13.7	9
96	Standardising the reporting of microbiology and antimicrobial susceptibility data. Lancet Infectious Diseases, The, 2019, 19, 1163-1164.	9.1	8
97	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1579-1589.	9.1	8
98	Geographical distribution of Burkholderia pseudomallei in soil in Myanmar. PLoS Neglected Tropical Diseases, 2021, 15, e0009372.	3.0	7
99	Epidemiology of Extended-Spectrum Beta-Lactamase and Carbapenemase-Producing Enterobacterales in the Greater Mekong Subregion: A Systematic-Review and Meta-Analysis of Risk Factors Associated With Extended-Spectrum Beta-Lactamase and Carbapenemase Isolation. Frontiers in Microbiology, 2021, 12, 695027.	3.5	7
100	Antimicrobial resistance detection in Southeast Asian hospitals is critically important from both patient and societal perspectives, but what is its cost?. PLOS Global Public Health, 2021, 1, e0000018.	1.6	6
101	Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia, and Southeast Asia: a systematic review of published etiological studies from 1980-2015. International Journal of Infectious Diseases, 2022, 122, 612-621.	3.3	6
102	Presence of Burkholderia pseudomallei in the â€~Granary of Myanmar'. Tropical Medicine and Infectious Disease, 2019, 4, 8.	2.3	5
103	Serological evidence indicates widespread distribution of rickettsioses in Myanmar. International Journal of Infectious Diseases, 2021, 103, 494-501.	3.3	5
104	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV). Wellcome Open Research, 0, 5, 241.	1.8	5
105	A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. PLoS Genetics, 2020, 16, e1009037.	3.5	5
106	A case–control study of the causes of acute respiratory infection among hospitalized patients in Northeastern Laos. Scientific Reports, 2022, 12, 939.	3.3	5
107	The effect of dose on the antimalarial efficacy of artesunate-mefloquine againstPlasmodium falciparummalaria: a protocol for systematic review and individual patient data (IPD) meta-analysis. BMJ Open, 2019, 9, e027738.	1.9	4

108 Case-based surveillance of antimicrobial resistance in the ACORN (A Clinically Oriented Antimicrobial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf

#	Article	IF	CITATIONS
109	Setting priorities for patient-centered surveillance of drug-resistant infections. International Journal of Infectious Diseases, 2020, 97, 60-65.	3.3	4
110	Observational study of adult respiratory infections in primary care clinics in Myanmar: understanding the burden of melioidosis, tuberculosis and other infections not covered by empirical treatment regimes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, 115, 914-921.	1.8	4
111	The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis. PLoS Medicine, 2021, 18, e1003766.	8.4	4
112	A Bayesian phase 2 model based adaptive design to optimise antivenom dosing: Application to a dose-finding trial for a novel Russell's viper antivenom in Myanmar. PLoS Neglected Tropical Diseases, 2020, 14, e0008109.	3.0	4
113	Evaluation of trends in hospital antimicrobial use in the Lao PDR using repeated point-prevalence surveys-evidence to improve treatment guideline use. The Lancet Regional Health - Western Pacific, 2022, 27, 100531.	2.9	4
114	The utility of an AMR dictionary as an educational tool to improve public understanding of antimicrobial resistance. Wellcome Open Research, 0, 6, 113.	1.8	3
115	High burden of infections caused by ESBL-producing MDR Escherichia coli in paediatric patients, Yangon, Myanmar. JAC-Antimicrobial Resistance, 2021, 3, dlab011.	2.1	3
116	Nitrofurantoin and glucose-6-phosphate dehydrogenase deficiency: a safety review. JAC-Antimicrobial Resistance, 2022, 4, dlac045.	2.1	3
117	Investment in antimalarial drug development is bearing fruit. Lancet Infectious Diseases, The, 2017, 17, 568-570.	9.1	2
118	Plasmodium falciparum ATP4 inhibitors to treat malaria: worthy successors to artemisinin?. Lancet Infectious Diseases, The, 2020, 20, 883-885.	9.1	2
119	Inter-prescriber variability in the decision to prescribe antibiotics to febrile patients attending primary care in Myanmar. JAC-Antimicrobial Resistance, 2021, 3, dlaa118.	2.1	2
120	Enhanced melioidosis surveillance in patients attending four tertiary hospitals in Yangon, Myanmar. Epidemiology and Infection, 2021, 149, 1-23.	2.1	2
121	Climate change and health in Southeast Asia – defining research priorities and the role of the Wellcome Trust Africa Asia Programmes. Wellcome Open Research, 0, 6, 278.	1.8	2
122	Antimicrobial resistance in commensal opportunistic pathogens isolated from non-sterile sites can be an effective proxy for surveillance in bloodstream infections. Scientific Reports, 2021, 11, 23359.	3.3	2
123	Dengue diagnostic test use to identify Aedes-borne disease hotspots. Lancet Planetary Health, The, 2021, 5, e503.	11.4	1
124	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Research, 0, 6, 216.	1.8	1
125	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
126	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1

#	Article	IF	CITATIONS
127	STARTER Checklist for Antimalarial Therapeutic Efficacy Reporting. American Journal of Tropical Medicine and Hygiene, 2022, 107, 1-3.	1.4	1
128	Keystone Malaria Symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment. Trends in Parasitology, 2022, 38, 711-718.	3.3	1
129	Post-malaria neurological syndromes. Clinical Medicine, 2017, 17, 95.	1.9	0
130	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Research, 0, 6, 216.	1.8	0
131	Utility of InTray COLOREX Screen agar and InTray COLOREX ESBL agar for urine culture in the Lao PDR. JAC-Antimicrobial Resistance, 2021, 4, dlac006.	2.1	0
132	Title is missing!. , 2020, 16, e1009037.		0
133	Title is missing!. , 2020, 16, e1009037.		Ο
134	Title is missing!. , 2020, 16, e1009037.		0
135	Title is missing!. , 2020, 16, e1009037.		0
136	Title is missing!. , 2020, 17, e1003393.		0
137	Title is missing!. , 2020, 17, e1003393.		0
138	Title is missing!. , 2020, 17, e1003393.		0
139	Title is missing!. , 2020, 17, e1003393.		Ο
140	Title is missing!. , 2020, 17, e1003393.		0
141	Title is missing!. , 2020, 14, e0008109.		0
142	Title is missing!. , 2020, 14, e0008109.		0
143	Title is missing!. , 2020, 14, e0008109.		0
144	Title is missing $2020, 14, 2000, 100$		

144 Title is missing!. , 2020, 14, e0008109.

0